The topical route for the delivery of drugs is essential in dermatology: it optimizes the penetration of medicaments, and when performed with the assistance of lasers, it takes place in a uniform and controlled manner. The degree of evidence of drug delivery is being investigated for many drugs. Moreover, the technique combines outstandingly with lasers for rejuvenation and treatment of skin diseases. It is therefore possible to conclude that the use of lasers for drug delivery is promising. While there are clinical studies on some substances that allow their indication and use, others require further controlled analyses, with longer follow-up periods, aimed at allowing thorough evaluations.

Keywords: LASERS; ADMINISTRATION, CUTANEOUS; SKIN ABSORPTION; DRUG DELIVERY SYSTEMS; DRUG ADMINISTRATION ROUTES

Six patients underwent two sessions of microneedling associated to drug delivery on the face, hands or stretch marks, at three-week interval between sessions. Patients were evaluated using clinical analysis and objective measures. Compared to baseline, objective face analysis showed decrease in acne lesions and improvement in the skin texture. The evaluation of stretch marks showed great improvement, and face and hands presented excellent results compared to baseline. The association of microneedling to drug delivery for rejuvenation of the face and hands, and for the treatment of stretch marks presented promising results in our study.

Keywords: ADMINISTRATION, CUTANEOUS; HYALURONIC ACID; REJUVENATION; STRIAE DISTENSAE; TRANEXAMIC ACID; HYDROXYPROLINE

INTRODUCTION: Advanced glycation end products (AGEs) are stable compounds formed by nonenzymatic reactions between amino groups of biomacromolecules and carbonyl groups of reducing sugars. AGEs are known to play a role in various diseases such as diabetes, cardiovascular diseases, and neurodegenerative disorders, as well as contributing to premature skin aging. Decarboxy carcinine HCl, a stable analogue of carnosine, has demonstrated potential in reducing the effects of glycation.
OBJECTIVE: To evaluate the effects of oral supplementation with Glycoxil^®, a patented decarboxy carcinine HCl molecule, on signs of skin aging in participants with mature skin.
METHODS: This randomized, double-blind, placebo-controlled study involved 30 participants aged 30-50 years, with skin phototypes I to IV and clinical signs of skin aging (e.g., rhytids). Participants were divided into two groups: one received Glycoxil^® 300 mg daily for 90 days, while the other received a placebo. Standardized skincare products were provided, and participants underwent evaluations using Visia^® and Focco^® imaging systems at baseline (T0), 45 days (T45), and 90 days (T90). Statistical analysis was conducted using RStudio, with ANOVA and Wilcoxon tests. Significance was set at p<0.05.
RESULTS: Of the 30 participants, 18 were analyzed with Focco^® and 22 with Visia^®. Objective evaluations showed no statistical differences between groups in rhytid improvement at T0, T45, or T90. However, slight improvements were observed in the treatment group at T45 and T90. Blinded dermatologists noted improvements in hydration, firmness, and texture in both groups, with some participants in the treatment group reporting "improved" or "much improved" appearance. No adverse effects were reported.
CONCLUSIONS: Although no statistically significant differences were found between the groups, the findings suggest that Glycoxil^® may contribute to minor improvements in skin-aging signs, corroborating existing literature on anti-glycation strategies. Further studies with larger sample sizes, extended follow-up periods, and advanced analytical methods are recommended to confirm these preliminary results.

Keywords: Glycation End Products, Advanced; Antiglycation Agents; Maillard Reaction.